Potential Immunotherapeutics for Immunosuppression in Sepsis.

about

AWRK6, A Synthetic Cationic Peptide Derived from Antimicrobial Peptide Dybowskin-2CDYa, Inhibits Lipopolysaccharide-Induced Inflammatory Response.

P2860

Q49804407-A8DF24C7-7FB1-459F-92DB-48842E37F23B

P2860

Potential Immunotherapeutics for Immunosuppression in Sepsis.

Item

http://www.wikidata.org/entity/Q47102338

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Potential Immunotherapeutics for Immunosuppression in Sepsis.

@en

Potential Immunotherapeutics for Immunosuppression in Sepsis.

@nl

type

Item

label

Potential Immunotherapeutics for Immunosuppression in Sepsis.

@en

Potential Immunotherapeutics for Immunosuppression in Sepsis.

@nl

prefLabel

Potential Immunotherapeutics for Immunosuppression in Sepsis.

@en

Potential Immunotherapeutics for Immunosuppression in Sepsis.

@nl

P1476

Potential Immunotherapeutics for Immunosuppression in Sepsis.

@en

P2093

Jinwook Shin

http://www.w3.org/2001/XMLSchema#string

Mirim Jin

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology of severe sepsis

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Viral immune evasion due to persistence of activated T cells without effector function

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies

Molecular mechanisms of T cell co-stimulation and co-inhibition

Drotrecogin alfa (activated)...a sad final fizzle to a roller-coaster party

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

P304

569-577

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4062/BIOMOLTHER.2017.193

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29081088

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

immunosuppression

sepsis

P932

5685425

http://www.w3.org/2001/XMLSchema#string

Potential Immunotherapeutics for Immunosuppression in Sepsis.

about

P2860

P2860

Potential Immunotherapeutics for Immunosuppression in Sepsis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932